Trials / Terminated
TerminatedNCT00137345
Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients
A Randomized, Open-Label, Comparative Evaluation of the Safety and Efficacy of Sirolimus Versus Cyclosporine When Combined in a Regimen Containing Basiliximab, Mycophenolate Mofetil, and Corticosteroids in Primary De Novo Renal Allograft Recipients
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 500 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if one drug is superior to another with regard to safety and the preservation of renal function after a kidney transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sirolimus |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-08-29
- Last updated
- 2013-02-08
Locations
82 sites across 21 countries: United States, Argentina, Australia, Austria, Canada, Chile, Cyprus, France, Germany, Greece, Hungary, Italy, Norway, Portugal, Singapore, South Africa, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00137345. Inclusion in this directory is not an endorsement.